ImmunoPrecise Antibodies (IPA) announces new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENSai platform, with a direct comparison to gold-standard wet-lab methods. The results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. LENSai’s AI-powered platform was able to match the performance of x-ray crystallography-the industry’s most precise but slowest and most expensive method-using sequence data alone.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPA:
- ImmunoPrecise Antibodies: Positioned for Growth with AI-Driven Drug Development Amid FDA Policy Shifts
- ImmunoPrecise Antibodies Aligns with FDA’s Move to Non-Animal Testing
- ImmunoPrecise Antibodies Partners with RIBOPRO to Enhance Antibody Discovery
- ImmunoPrecise Antibodies: Strategic Partnerships and Proprietary Platforms Drive Speculative Buy Rating
- ImmunoPrecise Antibodies Earnings Call Highlights Growth
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue